Befilac

# Befilac ## Overview - **Classification**: Selective Cyclooxygenase-2 (COX-2) Inhibitor - **Mechanism**: Potently inhibits COX-2, reducing prostaglandin synthesis, leading to anti-inflammatory, analgesic, and antipyretic effects while theoretically sparing COX-1 mediated gastric protection. ## Primary Indications 1. **Osteoarthritis (OA)** - Symptomatic relief of pain and inflammation. 2. **Rheumatoid Arthritis (RA)** - Management of pain and inflammation. 3. **Acute Pain** - Short-term relief of mild to moderate acute pain. ## Adult Dosing ### Standard Dosing **Osteoarthritis (OA) & Rheumatoid Arthritis (RA)** - **Dose**: **50 mg** - **Frequency**: Once daily (QD) - **Route**: Oral - **Duration**: Chronic, as needed for symptoms. **Acute Pain** - **Dose**: **100 mg** - **Frequency**: Once daily (QD) - **Route**: Oral - **Maximum Dose**: **100 mg/day** for acute pain. - **Special Considerations**: Use for shortest duration possible. ### Dose Adjustments - **Renal Impairment**: - CrCl 30-60 mL/min: Reduce dose by 25%. Max **75 mg/day**. - CrCl <30 mL/min: Not recommended due to increased risk of renal adverse effects. - **Hepatic Impairment**: - Mild to Moderate (Child-Pugh A-B): Reduce starting dose to **25 mg** QD. Monitor closely. - Severe (Child-Pugh C): Contraindicated. - **Elderly Patients**: Start at lower end of dosing range, e.g., **25 mg** QD. Monitor for renal/GI adverse effects. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: Not recommended. - **Special Notes**: Safety and efficacy not established. Potential for serious renal and cardiac adverse effects. ### Infants (1-12 months) - **Dose**: Not recommended. - **Special Notes**: Limited data. Consider alternative agents due to organ immaturity risks. ### Children (1-12 years) - **Indication**: Limited to specific inflammatory conditions under specialist supervision. - **Dose**: **0.5 mg/kg** - **Frequency**: Once daily (QD) - **Maximum**: **50 mg/day** (or **0.75 mg/kg** max if single higher dose needed for acute pain, not exceeding **75 mg**). - **Special Notes**: Use lowest effective dose for shortest duration. Monitor renal function. ### Adolescents (13-18 years) - **Dose**: Use adult dosing guidelines (**50 mg** QD for chronic conditions; **100 mg** QD for acute pain). - **Maximum**: **100 mg/day**. - **Special Notes**: Consider lower starting doses in smaller adolescents. Monitor for adult-like adverse effects. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to befilac or sulfonamides. - **Absolute**: History of asthma, urticaria, or allergic-type reactions after aspirin or other NSAIDs. - **Absolute**: Severe heart failure (NYHA Class III-IV), established ischemic heart disease, peripheral arterial disease, and/or cerebrovascular disease. - **Absolute**: Active gastrointestinal bleeding or ulceration. - **Absolute**: Severe renal impairment (CrCl <30 mL/min) or severe hepatic impairment (Child-Pugh C). - **Absolute**: Third trimester of pregnancy. ### Common Adverse Effects - **Very Common (>10%)**: Headache, Dyspepsia, Abdominal pain - **Common (1-10%)**: Nausea, Diarrhea, Peripheral edema, Hypertension, Rash - **Serious but Rare**: Gastrointestinal ulceration/bleeding, Myocardial infarction, Stroke, Renal failure, Anaphylaxis, Stevens-Johnson syndrome. ### Key Drug Interactions - **Warfarin**: Increased risk of bleeding. Monitor INR closely, adjust warfarin dose. - **ACE Inhibitors/ARBs**: Decreased antihypertensive effect, increased risk of renal impairment. Monitor blood pressure and renal function. - **Loop Diuretics/Thiazide Diuretics**: Reduced natriuretic effect. Monitor for fluid retention and efficacy of diuretic. - **SSRIs/SNRIs**: Increased risk of GI bleeding. Use with caution, consider proton pump inhibitor. - **Lithium**: Increased lithium plasma levels, risk of toxicity. Monitor lithium levels. - **Methotrexate**: Increased methotrexate levels, risk of toxicity. Monitor for adverse effects. ## Monitoring & Follow-up - **Before Treatment**: Baseline renal function (SCr, CrCl), liver function tests (ALT, AST), blood pressure. - **During Treatment**: - **Blood Pressure**: Regularly, especially in hypertensive patients. - **Renal Function**: Periodically, particularly in elderly or those with risk factors (e.g., every 6-12 months). - **Liver Function**: If symptoms of hepatic dysfunction appear. - **GI Symptoms**: Monitor for signs of bleeding (e.g., black stools, persistent abdominal pain). - **Clinical Signs**: Watch for edema, unexplained weight gain, severe headache, vision changes, signs of allergic reaction. ## Clinical Pearls - 💡 **Tip 1**: Administer **with food** or milk to minimize GI upset. - 💡 **Tip 2**: For chronic use, prescribe the **lowest effective dose** for the shortest duration necessary to control symptoms. - 💡 **Tip 3**: Counsel patients on increased risk of **cardiovascular events** (heart attack, stroke) and **gastrointestinal bleeding**. - 💡 **Tip 4**: Advise patients to report any unusual bleeding, persistent indigestion, swelling, or changes in urine output. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.